Article successfully added.

CyFlow™ CD253 Low Endotoxin

CyFlow™ CD253 Low Endotoxin
Alternative Name: Apo-2L, Apo2L, TNF-Related Apoptosis Inducing Ligand, TNFSF10, TRAIL
Antibody: Yes
Antigen: CD253
Application: Flow cytometry, Functional assays
Clonality: monoclonal
Clone: 2E5
Field of Interest: Apoptosis, Immunophenotyping
Format/Fluorochrome: Low Endotoxin
Isotype: IgG1
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: AM151429

For Research Use Only

$130.00 USD*

Price excludes any applicable taxes plus shipping costs

Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Volume 0.1 mL... more
CyFlow™ CD253 Low Endotoxin
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenRecombinant soluble fragment (aa 95-281) of human TRAIL
Background InformationCD253 (TRAIL; TNF-Related Apoptosis Inducing Ligand or Apo2) is a type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261 / TRAIL-R1) and DR5 (CD262 / TRAIL-R2).
Storage BufferThe reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T: TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 2002 Jan; 16(1):67‑73. < PMID: 11840265 > | Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC: Synthetic triterpenoids cooperate with tumor necrosis factor‑related apoptosis‑inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005 Jun 1; 65(11):4799‑808. < PMID: 15930300 >